Using Sildenafil to Reduce Bleeding During Liver Surgery
Preoperative Sildenafil Administration for Hepatectomy
NA · First People's Hospital of Chenzhou · NCT06237751
This study is testing if using Sildenafil during liver surgery can help reduce bleeding and improve the surgical conditions for patients.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 16 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | First People's Hospital of Chenzhou (other) |
| Locations | 1 site (Chenzhou, Hunan) |
| Trial ID | NCT06237751 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Sildenafil, a medication known for its vasodilating properties, to reduce intraoperative bleeding during liver surgeries (hepatectomies). The study employs the Control Low Central Venous Pressure (CLCVP) technique, which combines fluid restriction and vasodilators to manage blood loss. Primary outcomes include measuring intraoperative blood loss and evaluating the surgical field conditions, while secondary outcomes assess hemodynamic parameters and nitroglycerine usage. The trial aims to provide a more effective approach to managing bleeding complications in liver surgeries.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-85 who are scheduled for hepatic resection and meet specific health criteria.
Not a fit: Patients with severe cardiovascular diseases, renal impairment, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce intraoperative bleeding and improve surgical outcomes for patients undergoing liver surgery.
How similar studies have performed: While the use of Sildenafil in this context is relatively novel, similar studies exploring vasodilators in surgical settings have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing hepatic resection * age from 18-85 years * Child-Pugh ≤B * ASA II-III * willing to join the trial. Exclusion Criteria: * Pregnancy or Lactation * Known Allergy to any Medications used in the Study * Hemoglobin (Hb) \< 90 g/L * Body Mass Index (BMI) \> 35 kg/m2 or \< 18 kg/m2 * Hypertension \> 180 mmHg * Renal Impairment (Creatinine, Cr 178 µmol/L) * Severe Cardiovascular Diseases including Active Coronary Artery Disease, Severe Valve Stenosis and Hypertrophic Obstructive Cardiomyopathy, History of Stroke Within Six Months.
Where this trial is running
Chenzhou, Hunan
- Zhiming Zhang — Chenzhou, Hunan, China (RECRUITING)
Study contacts
- Principal investigator: Zhi-ming Z Zhang — Chenzhou NO. 1 people's Hospital
- Study coordinator: Qisheng Z Chen
- Email: cqs19990715@163.com
- Phone: +8618711451175
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Central Venous Pressure, Hepatectomy, Hemodynamics Instability, Sildenafil, Sildenafil Citrate, Laparoscopy, Low central venous pressure, Study protocol